Late Investigations, Reports Result in Form 483 for Hospira

FDA investigators rapped injectable giant Hospira for an inadequate response to findings of glass particles in drugs, resulting in a Form 483 for the drugmaker. During a July to August inspection of the drugmaker’s McPherson, Kan., facility, investigators found inspections into glass particles found in sterile lyophilized drugs were conducted long after discovery.
Drug GMP Report